Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib in VEXAS syndrome with or without associated myelodysplastic syndrome
2024-519779-24-00Phase 2Authorised
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivavotinib in VEXAS syndrome (VEXAS) and myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Dose-limiting toxicities and maximal tolerated dose and Overall clinical response rate. Planned start Nov 2025; status: authorised.
02
Drugs
mivavotinib
03
Conditions
VEXAS syndrome (VEXAS)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-519779-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519779-24-00.